Starling Oncology, Inc. STLN
4.00 USD +0.38 (+10.50%)
At closeNov 10, 2026, 4:53 AM EST
4.00 0.00 0.00%
Pre-market · Nov 10, 4:53 AM ET
3.50 Day range 4.52
2.32 52-week range 7.13
- YTD
- +12.36%
- 1 year
- +12.68%
News
benzinga.com B. Riley Securities Reiterates Buy on Starling Oncology, Lowers Price Target to $10 B. Riley Securities analyst Yuan Zhi reiterates Starling Oncology (NASDAQ:STLN) with a Buy and lowers the price target from $11 to $10.
marketbeat.com Oncology Institute Q3 Earnings Call Highlights Oncology Institute NASDAQ: STLN, referred to as Starling Oncology by executives during its earnings call, reported a second consecutive quarter of positive adjusted EBITDA as specialty pharmacy…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 19.5% to $0.36 during Friday's pre-market session. The company's market cap stands at $27.1 million. Eton Pharmaceuticals (NASDAQ:ETON)…
benzinga.com BTIG Maintains Buy on Starling Oncology, Raises Price Target to $10 BTIG analyst David Larsen maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $9 to $10.
benzinga.com Starling Oncology Q3 2026 Earnings Call Transcript Starling Oncology (NASDAQ:STLN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com Starling Oncology Narrows FY2026 Sales Guidance from $650.000M-$670.000M to $650.000M-$660.000M vs $663.685M Est Starling Oncology (NASDAQ:STLN) narrows FY2026 sales outlook from $650.000 million-$670.000 million to $650.000 million-$660.000 million vs $663.685 million estimate.
benzinga.com Starling Oncology Q3 EPS $(0.13) Misses $(0.05) Estimate, Sales $169.767M Beat $169.047M Estimate Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 7.14 percent increase over losses of…- benzinga.com Needham Maintains Buy on Starling Oncology, Raises Price Target to $9 Needham analyst Matthew Shea maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $7 to $9.